Key result
Pre-diagnostic plasma adiponectin was associated with decreased colorectal cancer risk, whereas sVCAM-1 was associated with increased risk.
Why the study?
Are pre-diagnostic levels of adiponectin and sVCAM-1 associated with colorectal cancer risk?
Case-Control (n=150)
Are pre-diagnostic levels of adiponectin and sVCAM-1 associated with colorectal cancer risk?
Pre-diagnostic plasma adiponectin and sVCAM-1 levels may serve as predictive biomarkers for colorectal cancer risk.
Answers are grounded in this paper and cite their sources.
May identify pre-diagnostic biomarkers for colorectal cancer risk; hypothesis-generating and requires prospective validation before clinical use.
AIM: To examine the relationships between pre-diagnostic biomarkers and colorectal cancer risk and assess their relevance in predictive models. METHODS: A nested case-control study was designed to include all first primary incident colorectal cancer cases diagnosed between inclusion in the SUpplémentation en VItamines et Minéraux AntioXydants cohort in 1994 and the end of follow-up in 2007. Cases (n = 50) were matched with two randomly selected controls (n = 100). Conditional logistic regression models were used to investigate the associations between pre-diagnostic levels of hs-CRP, adiponectin, leptin, soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1, E-selectin, monocyte chemoattractant protein-1 and colorectal cancer risk. Area under the receiver operating curves (AUC) and relative integrated discrimination improvement (RIDI) statistics were used to assess the discriminatory potential of the models. RESULTS: Plasma adiponectin level was associated with decreased colorectal cancer risk (P for linear trend = 0.03). Quartiles of sVCAM-1 were associated with increased colorectal cancer risk (P for linear trend = 0.02). No association was observed with any of the other biomarkers. Compared to standard models with known risk factors, those including both adiponectin and sVCAM-1 had substantially improved performance for colorectal cancer risk prediction (P for AUC improvement = 0.01, RIDI = 26.5%). CONCLUSION: These results suggest that pre-diagnostic plasma adiponectin and sVCAM-1 levels are associated with decreased and increased colorectal cancer risk, respectively. These relationships must be confirmed in large validation studies.
No takes yet. Share an insight, caveat, or question.
Mathilde Touvier (2012) conducted a case-control in colorectal cancer (n=150). Pre-diagnostic levels of adiponectin and sVCAM-1 vs. Lower biomarker levels was evaluated on colorectal cancer risk (p=0.03). Pre-diagnostic plasma adiponectin was associated with decreased colorectal cancer risk, whereas sVCAM-1 was associated with increased risk.
Synapse has enriched 10 related papers. Consider them for comparative context: